Cargando…

HER2-LOW BREAST CANCER BRAIN METASTASES: INCIDENCE AND TREATMENT IMPLICATIONS

Brain metastases (BrM) are a major cause of morbidity and mortality among women with breast cancer (BC). Central nervous system (CNS)-penetrating systemic therapies for patients with HER2-negative BrM are lacking; given CNS activity of trastuzumab deruxtecan, efficacy for patients with HER2-low BrM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chehade, Rania, Nofech-Mozes, Sharon, Plotkin, Anna, Moravan, Veronika, Jerzak, Katarzyna J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337545/ http://dx.doi.org/10.1093/noajnl/vdad071.032

Ejemplares similares

EXPRESSION OF ANDROGEN RECEPTOR IN BREAST CANCER BRAIN METASTASES
por: Fan, Kevin Yijun, et al.
Publicado: (2023)

Androgen Receptor Is Expressed in the Majority of Breast Cancer Brain Metastases and Is Subtype-Dependent
por: Fan, Kevin Yijun, et al.
Publicado: (2023)

PD-L1 expression in breast cancer brain metastases
por: Chehade, Rania, et al.
Publicado: (2022)

61. EXPRESSION OF ANDROGEN RECEPTOR IN BREAST CANCER BRAIN METASTASIS
por: Qazi, Maleeha, et al.
Publicado: (2020)

MLH1 Methylation Testing as an Integral Component of Universal Endometrial Cancer Screening—A Critical Appraisal
por: Plotkin, Anna, et al.
Publicado: (2023)

Analysis of Rates of Brain Metastases and Association With Breast Cancer Subtypes in Ontario, Canada
por: Wang, Xin Ye, et al.
Publicado: (2022)

Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2(+):ERα(-) breast cancer
por: Liu, Jeffrey C., et al.
Publicado: (2017)

Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force
por: Faragalla, Hala, et al.
Publicado: (2023)

EMT in Breast Carcinoma—A Review
por: Felipe Lima, Joema, et al.
Publicado: (2016)

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ
por: Rakovitch, E, et al.
Publicado: (2012)

Karnofsky Performance Status (KPS) ≤60 Is Strongly Associated With Shorter Brain-Specific Progression-Free Survival Among Patients With Metastatic Breast Cancer With Brain Metastases
por: Freeman, Mark, et al.
Publicado: (2022)

Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
por: Moss, Nelson S., et al.
Publicado: (2023)

Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study
por: Habbous, Steven, et al.
Publicado: (2020)

A Cluster-then-label Semi-supervised Learning Approach for Pathology Image Classification
por: Peikari, Mohammad, et al.
Publicado: (2018)

Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis
por: Erickson, Anders Wilder, et al.
Publicado: (2021)

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
por: Ferraro, Emanuela, et al.
Publicado: (2022)

Retroperitoneal Extraovarian Fibrothecoma Mimicking a Malignant Epithelial Ovarian Carcinoma
por: Roberts, Patrick, et al.
Publicado: (2012)

Intraoperative Assessment of Sentinel Lymph Nodes in Breast Cancer Patients Post-Neoadjuvant Therapy
por: Wong, Willard, et al.
Publicado: (2019)

HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis
por: Erickson, Anders W, et al.
Publicado: (2020)

Metastases to the breast
por: Arora, J, et al.
Publicado: (2008)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
por: Cai, Mengyuan, et al.
Publicado: (2023)

Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
por: Saleem, Azeem, et al.
Publicado: (2015)

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
por: Bartsch, R, et al.
Publicado: (2012)

Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
por: Yap, Y S, et al.
Publicado: (2012)

HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer
por: Da Silva, Leonard, et al.
Publicado: (2010)

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer
por: Maurer, Christian, et al.
Publicado: (2018)

Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
por: Garcia-Alvarez, Alejandro, et al.
Publicado: (2021)

Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
por: Yang, Xiaojing, et al.
Publicado: (2023)

Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
por: Ma, Xiaoping, et al.
Publicado: (2022)

Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
por: Saleem, Azeem, et al.
Publicado: (2017)

Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review
por: Giffoni de Mello Morais Mata, Danilo, et al.
Publicado: (2023)

Development of HER2-specific chimeric antigen receptor T cells for the treatment of breast-to-brain metastasis
por: Priceman, Saul, et al.
Publicado: (2015)

Pan-cancer classification of single cells in the tumour microenvironment
por: Nofech-Mozes, Ido, et al.
Publicado: (2023)

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
por: Jerzak, Katarzyna J., et al.
Publicado: (2023)

The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases
por: Chen, Xuelian, et al.
Publicado: (2023)

Response of Brain and Meningeal Metastases to Trastuzumab-Deruxtecan in a Patient with HER2-Low Breast Cancer: A Case Report
por: Wolf, Benita, et al.
Publicado: (2023)

74. EFFICACY OF HER2-TARGETED THERAPY IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A NATIONAL ANALYSIS
por: Hulsbergen, Alexander, et al.
Publicado: (2020)

SPIE-AAPM-NCI BreastPathQ Challenge: an image analysis challenge for quantitative tumor cellularity assessment in breast cancer histology images following neoadjuvant treatment
por: Petrick, Nicholas, et al.
Publicado: (2021)

Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis
por: Werter, Inge M., et al.
Publicado: (2022)

Predicting brain metastases of breast cancer based on serum S100B and serum HER2
por: BECHMANN, TROELS, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pkccmefe67d3l3vpk7jevastqe